Effective December 2025, the Respiratory Syncytial Virus (RSV) Investigator-Initiated Studies Program (MISP) Committee will accept protocols within our current Areas of Interest (AoIs) up to May 1, 2026. This is a competitive process that will be conducted by the RSV MISP Review Committee. Decisions will be made on the basis of scientific merit and strategic fit within the AoIs. Please review the critical activities and abide by the timelines as outlined below. The program requests that investigators specify how they will support diversity in enrollment to include traditionally underrepresented minorities/ethnic groups.
This is notification of approval of the Areas of Interest (AoIs) for RSV effective January 2026:
1. Changing epidemiology and burden of RSV disease:
- Infants/toddlers
- Immunocompromised hosts
- Older adults
2. Mechanistic studies concerning the immunocompromised
3. Clesrovimab concentrations in the nasal compartment
4. RSV antibody levels in older infants after receipt of RSV mAbs
5. Molecular/genetic evolution of RSV
6. RSV interactions with other respiratory viruses and bacteria
7. Use of clesrovimab in children and pre-surgery
8. Use of clesrovimab for the prevention of nosocomial infection
9. Implementation science:
- Operational implementation of clesrovimab